Credit: SciTechDaily.comThe diagnostic, which needs only a basic urine test to read the results, could make lung cancer evaluating more accessible worldwide.Using a brand-new technology established at MIT, diagnosing lung cancer could end up being as simple as breathing in nanoparticle sensors and then taking a urine test that reveals whether a tumor is present.The brand-new diagnostic is based on nanosensors that can be provided by an inhaler or a nebulizer. The epidemiology of lung cancer worldwide is that its driven by pollution and cigarette smoking, so we know that those are settings where accessibility to this kind of technology could have a big effect,” says Sangeeta Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science at MIT, and a member of MITs Koch Institute for Integrative Cancer Research and the Institute for Medical Engineering and Science.Bhatia is the senior author of the paper, which was published recently in Science Advances.”When we developed this technology, our goal was to supply a method that can detect cancer with high specificity and sensitivity, and also lower the limit for accessibility, so that ideally we can improve the resource variation and injustice in early detection of lung cancer,” Zhong says.Ease of Use and Potential for Early DetectionTo attain that, the researchers developed two solutions of their particles: a service that can be aerosolized and provided with a nebulizer, and a dry powder that can be delivered using an inhaler.Once the particles reach the lungs, they are taken in into the tissue, where they come across any proteases that may be present.”The concept would be you come in and then you get an answer about whether you require a follow-up test or not, and we could get patients who have early sores into the system so that they might get curative surgical treatment or lifesaving medications,” Bhatia says.Reference: “Inhalable point-of-care urinary diagnostic platform” by Qian Zhong, Edward K. W. Tan, Carmen Martin-Alonso, Tiziana Parisi, Liangliang Hao, Jesse D. Kirkpatrick, Tarek Fadel, Heather E. Fleming, Tyler Jacks and Sangeeta N. Bhatia, 5 January 2024, Science Advances.DOI: 10.1126/ sciadv.adj9591The research study was moneyed by the Johnson & & Johnson Lung Cancer Initiative, the Howard Hughes Medical Institute, the Koch Institute Support (core) Grant from the National Cancer Institute, and the National Institute of Environmental Health Sciences.Additional associated work was supported by the Marble Center for Cancer Nanomedicine and the Koch Institute Frontier Research Program through Upstage Lung Cancer.
Credit: SciTechDaily.comThe diagnostic, which needs only a simple urine test to check out the outcomes, could make lung cancer evaluating more accessible worldwide.Using a new technology established at MIT, detecting lung cancer could become as simple as inhaling nanoparticle sensing units and then taking a urine test that exposes whether a tumor is present.The new diagnostic is based on nanosensors that can be provided by an inhaler or a nebulizer.”When we developed this innovation, our goal was to provide a method that can find cancer with high uniqueness and level of sensitivity, and also lower the threshold for ease of access, so that ideally we can enhance the resource disparity and inequity in early detection of lung cancer,” Zhong says.Ease of Use and Potential for Early DetectionTo achieve that, the researchers created 2 solutions of their particles: a service that can be aerosolized and delivered with a nebulizer, and a dry powder that can be delivered utilizing an inhaler.Once the particles reach the lungs, they are absorbed into the tissue, where they encounter any proteases that might be present.”The idea would be you come in and then you get a response about whether you require a follow-up test or not, and we could get clients who have early lesions into the system so that they could get curative surgery or lifesaving medicines,” Bhatia says.Reference: “Inhalable point-of-care urinary diagnostic platform” by Qian Zhong, Edward K. W. Tan, Carmen Martin-Alonso, Tiziana Parisi, Liangliang Hao, Jesse D. Kirkpatrick, Tarek Fadel, Heather E. Fleming, Tyler Jacks and Sangeeta N. Bhatia, 5 January 2024, Science Advances.DOI: 10.1126/ sciadv.adj9591The research was moneyed by the Johnson & & Johnson Lung Cancer Initiative, the Howard Hughes Medical Institute, the Koch Institute Support (core) Grant from the National Cancer Institute, and the National Institute of Environmental Health Sciences.Additional related work was supported by the Marble Center for Cancer Nanomedicine and the Koch Institute Frontier Research Program by means of Upstage Lung Cancer.